How AXS-05 Works: The DXM/Bupropion Mechanism

AXS-05 treats agitation in Alzheimer’s disease by combining dextromethorphan (DXM) with bupropion, where bupropion’s primary role is to inhibit the CYP2D6-mediated metabolism of DXM, raising plasma concentrations of DXM to levels required for therapeutic effect. Without bupropion, DXM is rapidly broken down and fails to achieve the pharmacokinetic (PK) parameters necessary for NMDA receptor antagonism and sigma-1 receptor agonism — the two mechanisms of action central to the drug’s neuropsychiatric rationale.

Axsome Therapeutics’ patent filings, including US20230414494A1 and US20240189279A1, describe methods of treating agitation in patients with Alzheimer’s disease using DXM and bupropion, specifying that the methods comprise specific dosing regimens and achieve specific pharmacokinetic parameters of dextromethorphan. This PK-defined claim structure is significant: it establishes that the therapeutic value lies not just in the combination of molecules but in the precise systemic exposure profile that bupropion enables.

The same pharmacological rationale underpins Axsome’s approved product Auvelity (dextromethorphan/bupropion) for major depressive disorder (MDD). According to Axsome’s patent filings, the combination’s application extends across neurological and psychiatric conditions including depression, bipolar disorder, pseudobulbar affect, agitation, suicidality, smoking cessation, post-traumatic stress disorder, and pain — a breadth that reflects the platform potential of the CYP2D6-inhibition strategy. As documented by the FDA, the regulatory pathway for neuropsychiatric combinations requires demonstration of both the PK rationale and clinical efficacy in the target indication.

Axsome’s Patent Portfolio for Alzheimer’s Agitation: Depth and Breadth

Axsome Therapeutics has constructed one of the most extensive patent estates in the Alzheimer’s agitation space, with filings covering methods of treatment, specific dosing regimens, pharmacokinetic parameters, and pharmaceutical formulations — all centred on the DXM/bupropion combination. Patent publications span from early 2023 through late 2024 across US, WO (PCT), EP, and CN jurisdictions, signalling active global prosecution of the IP.

The portfolio architecture is layered across multiple claim types. Core method-of-treatment claims cover administering DXM and bupropion to patients with Alzheimer’s disease agitation. Downstream claims cover specific dosing regimens and the pharmacokinetic parameters of DXM achieved by those regimens. A separate formulation patent family (WO2024206440A1, US20240189282A1) covers the pharmaceutical formulations themselves — adding a further layer of protection beyond method claims. This multi-layer approach is consistent with best-practice IP strategy for combination drug products, as described in guidance from WIPO.

“Axsome’s patent filings claim not just the combination of molecules, but the specific pharmacokinetic parameters achieved — a strategy that ties IP protection directly to the clinical evidence generated in trials.”

Key granted US patents in the agitation indication include US11723887B2 (granted August 2023) and US12097179B1 (granted September 2024), with the most recent granted patent covering methods of treating Alzheimer’s disease agitation comprising specific dosing regimens and PK parameters of DXM. The PCT filing WO2024206436A1, published October 2024, further extends claims to specific efficacy and safety parameters of the treatment — a forward-looking claim structure that anticipates clinical trial outcomes.

Brexpiprazole: The Approved Benchmark Competitor AXS-05 Must Displace

Brexpiprazole (Rexulti), developed by Otsuka Pharmaceutical, is the first and currently only FDA-approved drug specifically indicated for agitation associated with Alzheimer’s dementia, having received that approval in May 2023. Any commercial case for AXS-05 in this indication must therefore be made against an already-approved, already-prescribing competitor — a materially different challenge from entering a virgin market.

Otsuka’s patent strategy mirrors Axsome’s in its layered depth. Multiple granted US patents cover methods of treating agitation associated with Alzheimer’s disease using brexpiprazole, including US11826358B2 (November 2023), US11890279B2 (February 2024), and US12059408B2 (August 2024). The most recent filings extend beyond core treatment claims into caregiver burden reduction (WO2024151726A1) and improvement of daily living (US20240197729A1) — a deliberate strategy to build a real-world evidence and label expansion moat around the approved indication. According to the European Medicines Agency, caregiver outcomes are increasingly considered in the benefit-risk assessment of dementia treatments.

The mechanism of brexpiprazole is fundamentally different from AXS-05. Brexpiprazole acts as a dopamine D2/D3 partial agonist — a pharmacological class that includes other atypical antipsychotics. Otsuka’s patent filings (US20240108613A1) describe the composition as a dopamine D2/D3 agonist administered orally for agitation associated with Alzheimer’s disease. The mechanistic differentiation between brexpiprazole’s dopaminergic action and AXS-05’s NMDA/sigma-1 approach is central to Axsome’s clinical and commercial positioning: the argument that a different mechanism may offer distinct efficacy or tolerability profiles in a patient population that has historically been managed off-label with antipsychotics carrying black-box warnings.

Avanir’s DXM/Quinidine Strategy: A Parallel DXM Approach to the Same Indication

Avanir Pharmaceuticals has filed patents covering methods of treating agitation associated with Alzheimer’s disease and other dementias using dextromethorphan and quinidine — a distinct formulation that uses a different CYP2D6 inhibitor from AXS-05’s bupropion. The active molecule (DXM) is shared with Axsome’s approach, but the metabolic inhibitor and the resulting pharmacokinetic profile differ, creating a separate IP and clinical pathway to the same indication.

Avanir’s DXM/quinidine combination is already commercialised as Nuedexta for pseudobulbar affect (PBA), giving the company an established regulatory and manufacturing foundation for the DXM/quinidine platform. The Alzheimer’s agitation patents (US20220110907A1, US20230346730A1) extend this platform into the dementia agitation space. The existence of this parallel DXM strategy is relevant to Axsome’s IP position: it demonstrates that the DXM-for-agitation concept is not proprietary to Axsome, but that the specific bupropion-based CYP2D6 inhibition approach and the PK parameters it achieves are the differentiating claim elements. According to the NIH, the pharmacokinetic differences between quinidine and bupropion as CYP2D6 inhibitors are clinically meaningful and may affect both efficacy and tolerability profiles.

The strategic implication for Axsome is that the Alzheimer’s agitation market may ultimately host two DXM-based products with different inhibitor profiles, in addition to brexpiprazole’s dopaminergic mechanism. Prescribers and payers will need to differentiate between these options based on clinical trial data, tolerability, drug-drug interaction profiles, and label language — all of which are shaped by the specific patent claims each company has prosecuted.

Emerging Diagnostics and the Broader Competitive Landscape

Beyond pharmacological treatments, the Alzheimer’s agitation space is attracting investment in diagnostic and monitoring technologies that could reshape how the indication is defined, measured, and treated. Emotiv Inc. has filed a patent (US20240138692A1) covering methods of detecting and predicting agitation in Alzheimer’s disease patients using EEG-based biomarkers — a technology that could provide objective measurement tools for a condition that is currently assessed through subjective clinical scales.

The emergence of EEG-based agitation biomarkers is relevant to the competitive landscape for AXS-05 and brexpiprazole in two ways. First, objective biomarkers could sharpen patient selection for clinical trials, potentially enabling more precise demonstration of treatment effects. Second, validated digital biomarkers could become companion tools that support prescribing decisions, creating a data layer that favours drugs whose efficacy is most clearly linked to measurable neurophysiological changes. The intersection of pharmacological and digital health approaches to neuropsychiatric conditions is an area of growing focus at IEEE and in the broader neurotechnology research community.

The overall competitive structure of the Alzheimer’s agitation space, as revealed by patent activity, can be summarised across three distinct pharmacological approaches: NMDA/sigma-1 modulation via DXM/bupropion (Axsome), dopamine D2/D3 partial agonism via brexpiprazole (Otsuka), and NMDA modulation via DXM/quinidine (Avanir). Each approach has a distinct mechanism, a distinct patent estate, and a distinct regulatory history. For IP professionals and R&D leaders evaluating this space, the patent landscape signals that agitation in Alzheimer’s disease is transitioning from an off-label prescribing practice — historically dominated by atypical antipsychotics with black-box warnings — to a formally contested, multi-compound indication with dedicated IP infrastructure.